Literature DB >> 7465354

[Hodgkin's disease: characteristics and prognosis of forms with initial bone marrow involvement (author's transl)].

C Jacquillat, G Auclerc, M F Auclerc, J M Andrieu, M Weil, J Bernard.   

Abstract

The distinctive features and prognosis of Hodgkin's disease with initial bone marrow involvement were studied in 53 patients. This form is characterized by clinical and biological signs of rapid evolution, diffuse lymphoid tissue involvement with enlarged liver and spleen, increased lymphocyte depletion and pancytopenia--the last named being rare in other forms. Sternberg cells were found in 80% of bone marrow biopsies, often associated which fibrosis, which always disappeared during remissions. Remission was obtained with multiple chemotherapy (chiefly MOPP) in 82% of the patients and was complet in 44%. Blood toxicity was severe in cases with myelofibrosis. Relapses occurred in 14 out of 39 patients and were either local and responsive to radiotherapy or diffuse and invariably lethal. They usually took place in those lymph nodes which were most affected initially. Additional radiotherapy and courses of MOPP reduce the risk of relapse. The long-term prognosis was similar to that of other visceral forms, with a survival rate leveling off at 83% after 6 years in patients in complete remission.

Entities:  

Mesh:

Year:  1981        PMID: 7465354

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  3 in total

1.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Lymphoproliferations in the bone marrow: identification and evolution, classification and staging.

Authors:  R Bartl; B Frisch; R Burkhardt; K Jäger; R Pappenberger; G Hoffmann-Fezer
Journal:  J Clin Pathol       Date:  1984-03       Impact factor: 3.411

3.  Hodgkin's disease diagnosed post mortem: a population based study.

Authors:  H Hasle; A Mellemgaard
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.